Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Euro Convergence brings regulatory peers from the EU and worldwide together in one forum to gain insights and exchange ideas on the region's most pressing issues. Register today to attend 10-12 May 2021.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
With contributions from more than 30 authors from seven countries, the new edition incorporates a global overview of the field and is designed to help you get the most out of your regulatory intelligence endeavors.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 05 September 2013 | By Alexander Gaffney, RAC,
The World Medical Association (WMA) has announced that its planned revisions to the Declaration of Helsinki, one of the most widely recognized ethical frameworks for the conduct of clinical studies, continues to move forward, with the most recent revision released to national medical associations-but not other stakeholders-as of 28 August 2013.
The Declaration of Helsinki was first adopted by the WMA during its Helsinki meeting in June 1964, and has since been amended eight additional times. Its most current revision, if formally adopted, would mark its tenth, and its fifth since the year 2000.
The document is known to be a major cornerstone of many countries' ethical frameworks for the governance of clinical trials.
Though an important landmark for ethical research standards, it is not legally binding for countries, industry or individuals. The US Food and Drug Administration (FDA), for instance, has not signed on to any revision made since 1996 after changes were made to abandon the use of placebo controls in studies where no therapeutic benefit currently exists.
Still, the declaration is often referenced as a benchmark for many other ethical frameworks. Until 2008, FDA required clinical trials conducted in foreign countries on behalf of pending products before the agency to adhere to the 1989 iteration of the declaration. Many other countries reference other versions of the declaration, such as the 1996 version referenced by the European Commission.
The WMA has been working on the draft document for months with an end goal of publication by 2014-the 50th anniversary of the initial declaration.
While initial revisions were first released publicly in April 2013, the WMA's members have been at work behind the scenes revising the update. At the organization's most recent meeting on 28 August 2013 in Washington, DC, the group agreed to circulate those changes to its 102 national medical association members.
In a statement, WMA said the final document would be debated-and possibly adopted-by WMA's General Assembly in October 2013.
One thing the public isn't likely to see before then: a copy of the proposed changes.
When reached for comment, WMA spokesman Nigel Duncan said he was unable to circulate the latest draft, explaining "it was decided at the end of the Washington meeting not to release the revised draft." Duncan added that he had not himself seen the draft, but did not expect it to be available until the Brazil meeting.
Which raises the question: How is industry-which runs a large percentage of all global clinical trials-supposed to know what's in the WMA draft before it's published?
While WMA's earlier draft included discussion of a number of controversial points, WMA's latest press statement indicates that topics that touched on "risks, burdens and benefits, informed consent and the use of placebo was of the highest order," implying that these sections have undergone further revisions.
"The draft changes to the Declaration incorporate increased protection for vulnerable groups and a strengthening of explicit ethical requirements for placebo use when a known effective treatment is available," WMA explained.
For now, industry will need to wait until October 2013 to see the proposed changes.
WMA Statement
Tags: WMA
Regulatory Focus newsletters
All the biggest regulatory news and happenings.